Use of immunomodulators and biologic therapies in children with inflammatory bowel disease

被引：13

作者：

Bousvaros, Athos ^{[1
]}

机构：

[1] Childrens Hosp Boston, Ctr Inflammatory Bowel Dis, Boston, MA 02115 USA

来源：

EXPERT REVIEW OF CLINICAL IMMUNOLOGY | 2010年 / 6卷 / 04期

关键词：

6-mercaptopurine; adalimumab; anti-tumor necrosis factor antibodies; azathioprine; certolizumab; child; Crohn's disease; inflammatory bowel disease; infliximab; methotrexate; natalizumab; pediatric; ulcerative colitis; NECROSIS-FACTOR-ALPHA; PEDIATRIC CROHNS-DISEASE; T-CELL LYMPHOMA; MAINTENANCE THERAPY; ULCERATIVE-COLITIS; INFLIXIMAB THERAPY; CERTOLIZUMAB PEGOL; GROWTH FAILURE; METHOTREXATE; 6-MERCAPTOPURINE;

D O I：

10.1586/ECI.10.46

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The immunomodulators (6-mercaptopurine, azathioprine and methotrexate) and biologics (infliximab, adalimumab, certolizumab and natalizumab) are medications essential in the management of pediatric inflammatory bowel disease. If properly utilized, these medications can control active disease, reduce corticosteroid exposure, induce remission, and promote normal growth and development. However, these medications also have significant toxicity and increase the risk of infections and lymphoma. This article provides information about the safety and efficacy of these medications in the treatment of children with Crohn's disease and ulcerative colitis.

引用

页码：659 / 666

页数：8

共 63 条

[1] Interleukin-6 inhibits growth hormone-mediated gene expression in hepatocytes [J].

Ahmed, Tamer A. ;

Buzzelli, Mark D. ;

Lang, Charles H. ;

Capen, John B. ;

Shumate, Margaret L. ;

Navaratnarajah, Maithili ;

Nagarajan, Murali ;

Cooney, Robert N. .

AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2007, 292 (06) :G1793-G1803

[2]

[Anonymous], 2007, J PEDIATR GASTR NUTR, V44, P653

[3] CHRONIC INTERMITTENT ELEMENTAL DIET IMPROVES GROWTH FAILURE IN CHILDREN WITH CROHNS-DISEASE [J].

BELLI, DC ;

SEIDMAN, E ;

BOUTHILLIER, L ;

WEBER, AM ;

ROY, CC ;

PLETINCX, M ;

BEAULIEU, M ;

MORIN, CL .

GASTROENTEROLOGY, 1988, 94 (03) :603-610

[4] Oral tacrolimus treatment of severe colitis in children [J].

Bousvaros, A ;

Kirschner, BS ;

Werlin, SL ;

Parker-Hartigan, L ;

Daum, F ;

Freeman, KB ;

Balint, JP ;

Day, AS ;

Griffiths, AM ;

Zurakowski, D ;

Ferry, GD ;

Leichtner, AM .

JOURNAL OF PEDIATRICS, 2000, 137 (06) :794-799

[5] Challenges in pediatric inflammatory bowel disease [J].

Bousvaros, Athos ;

Sylvester, Francisco ;

Kugathasan, Subra ;

Szigethy, Eva ;

Fiocchi, Claudio ;

Colletti, Richard ;

Otley, Anthony ;

Amre, Devendra ;

Ferry, George ;

Czinn, Steven J. ;

Splawski, Judy B. ;

Oliva-Hemker, Maria ;

Hyams, Jeffrey S. ;

Faubion, William A. ;

Kirschner, Barbara S. ;

Dubinsky, Marla C. .

INFLAMMATORY BOWEL DISEASES, 2006, 12 (09) :885-913

[6] Indeterminate colitis: A significant subgroup of pediatric IBD [J].

Carvalho, RS ;

Abadom, V ;

Dilworth, HP ;

Thompson, R ;

Oliva-Hemker, M ;

Cuffari, C .

INFLAMMATORY BOWEL DISEASES, 2006, 12 (04) :258-262

[7] Natalizumab and PML: a risky business? [J].

Clifford, David B. .

GUT, 2008, 57 (10) :1347-1349

[8] Comparison of Two Adalimumab Treatment Schedule Strategies for Moderate-to-Severe Crohn's Disease: Results From the CHARM Trial [J].

Colombel, Jean-Frederic ;

Sandborn, William J. ;

Rutgeerts, Paul ;

Kamm, Michael A. ;

Yu, Andrew P. ;

Wu, Eric Q. ;

Pollack, Paul F. ;

Lomax, Kathleen G. ;

Chao, Jingdong ;

Mulani, Parvez M. .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 (05) :1170-1179

[9] Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model [J].

Crandall, WV ;

Mackner, LM .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (01) :75-84

[10] Low-dose methotrexate: A mainstay in the treatment of rheumatoid arthritis [J].

Cronstein, BN .

PHARMACOLOGICAL REVIEWS, 2005, 57 (02) :163-172

← 1 2 3 4 5 6 7 →